Search company, investor...
Catalyst Biosciences company logo

Catalyst Biosciences

Founded Year



Corporate Majority - P2P | IPO

Total Raised


About Catalyst Biosciences

Catalyst Biosciences is developing next generation biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase therapeutics. Catalyst is focusing its product development efforts on drug candidates for hemophilia, non-hemophilic bleeding, and complement-driven diseases, including the prevention of delayed graft function and inflammation. The company was founded in 2003 and is based in South San francisco, California.

Headquarters Location

260 Littlefield Avenue

South San Francisco, California, 94080,

United States


Missing: Catalyst Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Catalyst Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Catalyst Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Catalyst Biosciences is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

1,568 items

Catalyst Biosciences Patents

Catalyst Biosciences has filed 32 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Coagulation system
  • Coagulopathies
patents chart

Application Date

Grant Date


Related Topics




Complement system, Immune system, Immunology, Clusters of differentiation, EC 3.4.21


Application Date


Grant Date



Related Topics

Complement system, Immune system, Immunology, Clusters of differentiation, EC 3.4.21



Latest Catalyst Biosciences News

Global Proteases Market Report 2017-2022, 2022-2027F, 2032F Featuring Advanced Enzymes Technologies, E.l. Du Pont de Nemours & Co, Amano Enzymes, Biocatalysts, & Koninklijke DSM

May 29, 2023

Dublin, IRELAND Dublin, May 29, 2023 (GLOBE NEWSWIRE) -- The "Proteases Global Market Report 2023" report has been added to's offering. The global proteases market is expected to grow from $2.99 billion in 2022 to $3.19 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The proteases market is expected to grow to $4.12 billion in 2027 at a CAGR of 6.6%. Proteases refer to a large and various group of enzymes that break down protein. Proteases break down proteins in the body or skin to help with digestion or with the breakdown of proteins causing swelling and pain. The main sources of proteases are animal, plant, and microbial. Animal proteases refer to enzymes that are originated from animals. Pancreatic trypsin, chymotrypsin, pepsin, and renin are some of the animal proteases. These are available in liquid and powder form that are used in applications such as food and beverage, healthcare, animal feed, and others Product innovation is a key trend gaining popularity in the protease market. Major players operating in the proteases market are focusing on innovating novel products to gain a completive advantage in the market. For instance, in September 2021, DSM-Novozymes Feed Enzymes Alliance, an association between DSM, a Netherlands-based chemicals company, and Novozymes A/S, a Denmark-based biotechnology company, launched ProAct 360, a novel and robust second-generation protease customized to the needs of the feed industry. The innovative proteases offer feed efficiency, sustainability, and affordability. It is more consistent, and releases more amino acids from the feed, thus, improving feed efficiency. It is specifically created for application in animal feed and it is the only feed protease available in the market. In May 2022, Vertex Pharmaceuticals, a US-based biopharmaceutical company acquired a portfolio of protease medicines from Catalyst Biosciences Inc for $60 million. The acquisition expands the product portfolio of Vertex with protease medicines and enables future growth. Catalyst Biosciences Inc is a US-based biotechnology company. North America was the largest region in the proteases market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the proteases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The rising number of health-conscious consumers is expected to drive the growth of the proteases market going forward. Health-conscious consumers (HCCs) are those consumers that live a 'wellness-oriented' lifestyle and are worried about their environment and nutrition. Health-conscious consumers are interested in the consumption of healthier products containing proteases that support digestive health and weight consciousness. For instance, according to a survey result published in January 2021 by Public Health England (PHE), an England-based government agency for health and social care, a survey of more than 5000 adults showed that 7 in 10 adults were motivated to make healthier lifestyle changes owing to COVID-19 pandemic while 8 in 10 adults aged over 18 decided to alter their lifestyle in 2021. Additionally, around 43% of adults feel more motivated to make changes to their life as compared to last year. Therefore, the rising number of health-conscious consumers will propel the demand for proteases. Key Attributes:

Catalyst Biosciences Frequently Asked Questions (FAQ)

  • When was Catalyst Biosciences founded?

    Catalyst Biosciences was founded in 2003.

  • Where is Catalyst Biosciences's headquarters?

    Catalyst Biosciences's headquarters is located at 260 Littlefield Avenue, South San Francisco.

  • What is Catalyst Biosciences's latest funding round?

    Catalyst Biosciences's latest funding round is Corporate Majority - P2P.

  • How much did Catalyst Biosciences raise?

    Catalyst Biosciences raised a total of $111.93M.

  • Who are the investors of Catalyst Biosciences?

    Investors of Catalyst Biosciences include GNI Group, Targacept, Sofinnova Ventures, Morgenthaler Ventures, EW Healthcare Partners and 9 more.

  • Who are Catalyst Biosciences's competitors?

    Competitors of Catalyst Biosciences include c-LEcta, LungLife AI, Bird Rock Bio, NGM Biopharmaceuticals, PhaseBio Pharmaceuticals and 16 more.

Compare Catalyst Biosciences to Competitors

LungLife AI Logo
LungLife AI

LungLife AI is focused on the development of the LiquidBiopsy platform, a high-performance rare cell isolation technology for biomedical research and cancer diagnostics. LiquidBiopsy is a key enabling technology to realize the promise of personalized medicine, including the early detection of disease, real-time monitoring of patients, and the selection of individual therapeutic solutions.

DNAtrix Logo

DNAtrix operates as a biotechnology company developing virus-driven immunotherapies to treat cancer. It develops modified viruses for the treatment of the most aggressive forms of cancer. The company was founded in 2005 and is based in Carlsbad, California.


RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.

Acureon Pharmaceuticals

ACUREON Pharmaceuticals is a United States biopharmaceutical company primarily focused on specialty therapeutics to improve patient outcomes in the hospital areas of Infectious Diseases, Transplant, and ICU. To address the needs of the market, Acureon Pharma is focused on exploring opportunities that selectively acquire and enhance the market potential of commercially available therapeutics and late-stage development drugs. The company is located in the western suburbs of Philadelphia.


AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.

Aphios Logo

Aphios is a clinical stage biotechnology company. It develops technology platfroms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, the company develops therapeutics to prevent disease, maintain health, and treat chronic diseases, including cancers and supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19. The company was founded in 2018 and is based in Woburn, Massachusetts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.